Carl June and the Novartis/Penn team weren't the only players to grab the spotlight at the global gathering of hematology experts at the big American Society of Hematology meeting in New Orleans. Several companies touted new data for their therapies over the weekend, and FierceBiotech focused on a roundup of the news related to some top contenders in the field.
The Cambridge, MA-based biotech has agreed to pay Takeda $15 million and in exchange Millennium is ripping up its option to bag a 50/50 split on any of Infinity's PI3K inhibitors, including the lead program for IPI-145.
Infinity Pharmaceuticals has cut 20% of its employees as the drug developer advances its lead candidates without R&D dollars from Mundipharma International, the company revealed Tuesday. And the company also blamed its recent decision to end development of its lead anti-cancer compound saridegib for the staff cutbacks.
Independent monitors stepped in to shut down another mid-stage cancer study of Infinity Pharmaceuticals' ($INFI) lead drug saridegib after concluding that the experimental therapy was performing no better than a placebo.
Infinity Pharmaceuticals' ($INFI) lead therapy failed a critical mid-stage hurdle as investigators moved to shut down a study for pancreatic cancer after the treatment in combination with a common
Infinity Pharmaceuticals ($INFI) has some new wiggle room in its budget to develop its PI3K inhibitor intended to combat blood cancers and inflammation. Mundipharma International, Infinity's partner
Infinity Pharmaceuticals, a 2005 Fierce 15 company, has scooped up the global development and commercialization rights to a portfolio of oral PI3K inhibitors developed by Intellikine, including one
Infinity Pharmaceuticals halted its late-stage trial of an experimental new therapy for gastrointestinal tumors after recording a higher mortality rate among the patients taking the drug. The news
With cash on hand to last it several years, Cambridge, MA-based Inifinity Pharma has laid out an aggressive growth plan that it says will put its first drug on the market and three other candidates
AstraZeneca has handed back the rights to two oncology programs it picked up in the 2007 acquisition of MedImmune. Infinity Pharmaceuticals gets the full rights to IPI-504 and IPI-493, both of which